Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (11): 1104-1105.DOI: 10.3969/j.issn.1673-8640.2022.011.021
Previous Articles Next Articles
Received:2021-08-05
Revised:2022-06-08
Online:2022-11-30
Published:2022-12-26
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.011.021
| 组别 | 例数 | CA125/ （U/mL） | Fib/ （g/L） | DD/ （μg/L） |
|---|---|---|---|---|
| 正常对照组 | 40 | 11.2±4.5 | 2.74±0.52 | 154.2±17.8 |
| 卵巢癌组 | 43 | 953.2±141.8* | 5.68±1.21* | 807.9±189.9* |
| 组别 | 例数 | CA125/ （U/mL） | Fib/ （g/L） | DD/ （μg/L） |
|---|---|---|---|---|
| 正常对照组 | 40 | 11.2±4.5 | 2.74±0.52 | 154.2±17.8 |
| 卵巢癌组 | 43 | 953.2±141.8* | 5.68±1.21* | 807.9±189.9* |
| 临床病理特征 | 例数 | Fib/（g/L） | DD/（μg/L） |
|---|---|---|---|
| 年龄 | |||
| <50岁 | 21 | 4.4±1.1 | 636.5±154.2 |
| ≥50岁 | 22 | 6.3±1.2* | 961.7±213.4* |
| FIGO病理分期 | |||
| Ⅰ~Ⅱ期 | 20 | 4.7±1.0 | 642.4±151.3 |
| Ⅲ~Ⅳ期 | 23 | 6.5±1.3# | 951.8±216.5# |
| 淋巴结转移 | |||
| 有 | 27 | 6.5±1.4 | 942.4±249.3 |
| 无 | 16 | 4.5±1.1△ | 651.8±146.5△ |
| 病理类型 | |||
| 浆液性 | 33 | 5.8±2.0 | 832.6±267.6 |
| 非浆液性 | 10 | 6.1±1.8 | 923.7±212.5 |
| 腹腔积液 | |||
| 有 | 29 | 6.7±0.9 | 941.4±218.8 |
| 无 | 14 | 4.6±1.1▲ | 648.8±134.3▲ |
| 临床病理特征 | 例数 | Fib/（g/L） | DD/（μg/L） |
|---|---|---|---|
| 年龄 | |||
| <50岁 | 21 | 4.4±1.1 | 636.5±154.2 |
| ≥50岁 | 22 | 6.3±1.2* | 961.7±213.4* |
| FIGO病理分期 | |||
| Ⅰ~Ⅱ期 | 20 | 4.7±1.0 | 642.4±151.3 |
| Ⅲ~Ⅳ期 | 23 | 6.5±1.3# | 951.8±216.5# |
| 淋巴结转移 | |||
| 有 | 27 | 6.5±1.4 | 942.4±249.3 |
| 无 | 16 | 4.5±1.1△ | 651.8±146.5△ |
| 病理类型 | |||
| 浆液性 | 33 | 5.8±2.0 | 832.6±267.6 |
| 非浆液性 | 10 | 6.1±1.8 | 923.7±212.5 |
| 腹腔积液 | |||
| 有 | 29 | 6.7±0.9 | 941.4±218.8 |
| 无 | 14 | 4.6±1.1▲ | 648.8±134.3▲ |
| 组别 | 例数 | CA125/ （U/mL） | Fib/ （g/L） | DD/ （μg/L） |
|---|---|---|---|---|
| 化疗有效组 | 29 | 64.3±10.6* | 2.8±0.8* | 482.3±79.9* |
| 化疗无效组 | 14 | 415.4±107.8 | 5.4±1.0 | 1 850.1±214.4 |
| 组别 | 例数 | CA125/ （U/mL） | Fib/ （g/L） | DD/ （μg/L） |
|---|---|---|---|---|
| 化疗有效组 | 29 | 64.3±10.6* | 2.8±0.8* | 482.3±79.9* |
| 化疗无效组 | 14 | 415.4±107.8 | 5.4±1.0 | 1 850.1±214.4 |
| [1] | 魏晓萍, 惠起源, 陈雅慧. 恶性肿瘤患者凝血和纤溶状况研究进展[J]. 临床荟萃, 2009, 24(5):453-454. |
| [2] | 许洁, 韩洪超, 崇庆国, 等. 血浆D-二聚体及血小板水平检测在以VTE为早期表现的恶性肿瘤中的意义[J]. 中国医师杂志, 2019, 21(4):596-598. |
| [3] | 陈峻, 徐升强, 曹文操. 原发性肝癌患者血浆D二聚体、纤溶酶-α2抗纤溶酶复合物联合检测的临床价[J]. 血栓与止血学, 2019, 25(1):27-28. |
| [4] | 邱云芬, 李建刚, 彭根大. 肿瘤相关抗原CA-125在卵巢癌诊断和监测中的应用[J]. 南通医学院学报, 2000, 20(3):243-244. |
| [5] | 许沈华, 应莉莎, 朱赤红, 等. 卵巢浆液性腺癌患者生存因素分析[J]. 临床与实验病理学杂志, 2011, 27(2):142-145. |
| [6] | 杨学宁, 吴一龙. 实体瘤治疗疗效评价标准-RECIST[J]. 循证医学, 2004, 4(2):85-90. |
| [7] |
EDWARDS R L, RICKLES F R, MORITZ T E, et al. Abnormalities of blood coagulation tests in patients with cancer[J]. Am J Clin Pathol, 1987, 88(5):596-602.
PMID |
| [8] |
PALUMBO J S, KOMBRINCK K W, DREW A F, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells[J]. Blood, 2000, 96(10):3302-3309.
PMID |
| [9] |
SAHAI E. Mechanisms of cancer cell invasion[J]. Curr Opin Genet Dev, 2005, 15(1):87-96.
PMID |
| [10] | 兰新志, 赵丹丹. 血浆D-二聚体、Fbg及CA125水平变化在卵巢癌中的临床意义[J]. 国际检验医学杂志, 2016, 37(23):3343-3345. |
| [11] |
BATSCHAUER A P B, FIGUEIREDO C P, BUENO E C, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer[J]. Ann Oncol, 2010, 21(6):1267-1272.
DOI PMID |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
